Our Technology Overview

Many traditional drugs when given orally exhibit poor and/or highly variable bioavailability and are often accompanied by significant gastro-intestinal side effects. The proprietary powder processing techniques developed by Nanotherapeutics improve the delivery of drugs that cannot normally be taken orally. Nanotherapeutics has developed new inhalation, nasal, injectable, and oral particle delivery systems that:

• Improve the safety and efficacy of low molecular weight drugs,


• Improve the stability and absorption of proteins that normally cannot be taken orally, and


• Extend the life cycle of many existing drug formulations.

Particle delivery systems (PDS) are of particular importance since there will be hundreds of new bio-engineered drugs entering the marketplace in the next few years that cannot be absorbed orally using traditional systems because of enzymatic breakdown. Sustained-release delivery systems have shown considerable promise within the industry since most peptides/proteins have short systemic half-lives and require that they be given by frequent injection or constant infusion, a situation generally not preferred by either patients or physicians.


Our technologies address these issues by:

• Providing a means to use non-invasive routes of administration rather than injection.
  

• Enhancing the systemic absorption (bioavailability) of insoluble compounds and macromolecules.
  

• Improving the consistency of absorption.
  

• Reducing the amount of dose required and potentially the frequency of dosing.
  
  

From a Pharmaceutical perspective, Nanotherapeutics' technologies provide:

• Innovative methods to manufacture nanoparticle formulations with controlled particle size, morphology and surface properties to improve handling, dispersion and absorption.
  
• Sustained-release profiles up to 24 hours to improve patient compliance with drug regimens.
  
• Specific formulations to improve stability and shelf life.